OTCMKTS:SEOVF Sernova Biotherapeutics (SEOVF) Stock Price, News & Analysis $0.14 +0.01 (+4.51%) As of 02:05 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Sernova Biotherapeutics Stock (OTCMKTS:SEOVF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SEOVF alerts:Sign Up Key Stats Today's Range$0.13▼$0.1450-Day Range$0.11▼$0.1652-Week Range$0.10▼$0.21Volume49,750 shsAverage Volume9,945 shsMarket Capitalization$45.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sernova Biotherapeutics is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes. In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation. Beyond diabetes, the company is exploring broader applications of its delivery platform, including therapies for hemophilia and other endocrine and metabolic disorders. Preclinical studies have demonstrated the ability of the Cell Pouch to promote cell engraftment and function, positioning Sernova’s technology as a potential alternative to conventional chronic drug administration. Founded in 2008 and formerly known as Sernova Corp, the company rebranded as Sernova Biotherapeutics in late 2023 to better reflect its evolving pipeline. Sernova conducts its clinical activities across North America and Europe, collaborating with academic and clinical research centers to advance its trials. Leading the organization is Dr. Philip A. Toleikis, Sernova’s founder, president and chief executive officer, who brings more than two decades of experience in regenerative medicine and cell‐based therapy development.AI Generated. May Contain Errors. Read More Receive SEOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sernova Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SEOVF Stock News HeadlinesSernova Biotherapeutics Announces Collaboration with Eledon ...July 11, 2025 | morningstar.comMSernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 DiabetesJuly 9, 2025 | globenewswire.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.September 15 at 2:00 AM | Brownstone Research (Ad)Sernova Biotherapeutics Taps CEO to Be Interim ChairJune 2, 2025 | marketwatch.comSernova Appoints Jonathan Rigby as Interim ChairJune 2, 2025 | globenewswire.comChair of Sernova Biotherapeutics ResignsMay 25, 2025 | globenewswire.comSernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 DiabetesMay 22, 2025 | globenewswire.comSernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 DiabetesMay 14, 2025 | globenewswire.comSee More Headlines SEOVF Stock Analysis - Frequently Asked Questions How have SEOVF shares performed this year? Sernova Biotherapeutics' stock was trading at $0.15 on January 1st, 2025. Since then, SEOVF stock has decreased by 7.3% and is now trading at $0.1390. How were Sernova Biotherapeutics' earnings last quarter? Sernova Biotherapeutics Inc. (OTCMKTS:SEOVF) posted its earnings results on Monday, September, 15th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Sernova Biotherapeutics? Shares of SEOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/15/2025Last Earnings9/15/2025Next Earnings (Estimated)9/15/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:SEOVF CIK1491434 Webwww.sernova.com Phone(519) 858-5184Fax519-858-5184EmployeesN/AYear Founded2006Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.65 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-396.49% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-4.63Miscellaneous Outstanding Shares328,480,000Free FloatN/AMarket Cap$45.66 million OptionableNot Optionable Beta1.07 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:SEOVF) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sernova Biotherapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sernova Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.